The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The company says the platform offers improved manufacturability and functional advantages
The approval clears the way for a US study at leading clinical centers to evaluate the safety and effectiveness of VDYNE’s system in patients
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
Subscribe To Our Newsletter & Stay Updated
